表紙
市場調査レポート

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:パイプライン製品の分析

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 271821
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:パイプライン製品の分析 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 48 Pages
概要

メチシリン感受性黄色ブドウ球菌 (MSSA) は、多数の抗生物質に対する耐性を持つ細菌です。MSSAは通常皮膚への感染がみられますが、肺炎やその他重篤な感染症を引き起こす場合があります。蜂巣炎、痛みを伴う発疹、悪心嘔吐、発熱、筋肉の痛み、下痢や腹痛などの症状があり、発病要因は免疫システムの低下、火傷、手術による創傷などです。

当レポートでは、メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:企業で開発中の治療薬

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:大学/機関で研究中の治療薬

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:企業で開発中の製品

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:大学/機関で研究中の製品

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症の治療薬開発に従事している企業

  • Arsanis Biosciences GmbH
  • ContraFect Corporation
  • Debiopharm International SA
  • Sealife PHARMA GMBH
  • 大日本住友製薬

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:最近のパイプライン動向

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:休止中のプロジェクト

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:開発が中止された製品

メチシリン感受性黄色ブドウ球菌 (MSSA) 感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8052IDB

Summary

Global Markets Direct's, 'Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2016', provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections
  • The report reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlists all their major and minor projects
  • The report assesses Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview
  • Therapeutics Development
    • Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
    • Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
    • Arsanis Biosciences GmbH
    • ContraFect Corporation
    • Debiopharm International SA
    • Sealife PHARMA GMBH
    • Sumitomo Dainippon Pharma Co., Ltd.
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ASN-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0904 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SLP-0905 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Oncology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Recent Pipeline Updates
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
    • Featured News & Press Releases
      • Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2016
  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA , H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H1 2016
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H1 2016
  • Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top